{
  "schemaVersion": 1,
  "id": "research-387",
  "slug": "387-what-researchers-observed-after-tirzepatide-withdrawal",
  "title": "What researchers observed after tirzepatide withdrawal",
  "catalogLabel": "TIRZ GLP-2",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tirz-glp-2",
  "productHandles": [
    "tirz-glp-2-692"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tirz-glp-2-692"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 335,
  "sourceYears": [
    2022,
    2025
  ],
  "paragraphs": [
    "A peptide is a short chain of amino acids connected by peptide bonds. Some can engage hormone receptors and alter the body’s response to meals. Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “TIRZ GLP-2” label identifies the catalog entry. In a later analysis of SURMOUNT-4, researchers examined how weight regain after withdrawal related to changes in blood pressure, waist circumference and other measures. [1, 2]",
    "In the main trial, participants initially received tirzepatide. Those who reached the randomized phase were assigned to continue treatment or switch to placebo. The later analysis focused on 308 people who switched to placebo and had previously lost at least 10% of their weight. It grouped them by the proportion of that prior loss they subsequently regained. Regaining 25% of weight previously lost describes a fraction of that earlier change. It does not mean an increase of 25% of total body weight. [1]",
    "Participants who regained a greater proportion generally had larger increases in waist circumference and systolic blood pressure. For example, the mean waist increase was less than a centimeter in the lowest regain category and about 15 centimeters in the highest. Other markers, including some blood lipid and glucose measures, also varied with the amount of regain. The groups describe patterns observed after withdrawal among the selected participants. [1]",
    "This analysis did not randomly assign participants to regain more or less weight. It grouped them according to what happened after the switch to placebo. Differences across the regain categories therefore cannot establish that weight change alone caused every change in the other measures. The study also focused on people who responded to the initial phase according to the analysis threshold, so its estimates do not describe everyone who has taken tirzepatide. [1]",
    "The evidence adds detail to a withdrawal trial by describing how several measures changed together. It helps separate the question of how often people regained weight from the question of which other observations were associated with that regain over the reported period. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Deborah B. Horn et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine (publication 2025-11-24).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41284285/"
    },
    {
      "number": 2,
      "citation": "Bingfa Sun et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences (publication 2022-03-25).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35333651/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/387-what-researchers-observed-after-tirzepatide-withdrawal",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/387-what-researchers-observed-after-tirzepatide-withdrawal.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/387-what-researchers-observed-after-tirzepatide-withdrawal.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 078 - TIRZ GLP-2 and TIRZ IGF-1 LR3.docx",
    "sourceArticleNumber": 387,
    "contentSha256": "9f372ceb899f566203811358e94ea47b31f6a938ab97286ba8199d782033b713",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
